Eli Lilly, Boehringer Ingelheim earn FDA approval for diabetes medication Synjardy

The Food and Drug Administration recently approved Synjardy XR, a diabetes medication developed by Indianapolis-based Eli Lilly & Co. and Ridgefield, Conn.-based Boehringer Ingelheim Pharmaceuticals.

Synjardy XR combines the glucose-lowering drugs empagliflozin and metformin. The drug is intended to improve blood glucose levels in adults with type 2 diabetes when used alongside diet and exercise.

"Adults with type 2 diabetes often take multiple medications, sometimes more than once a day, to manage their condition," said Paul Fonteyne, president and CEO of Boehringer Ingelheim Pharmaceuticals, in a news release. "With Synjardy XR, the eighth FDA-approved treatment to emerge from our partnership with Lilly, adults with type 2 diabetes now have another convenient daily option to help them reach their glycemic goals, whether they are already being treated or are just at the beginning of their treatment."

More articles on supply chain:

Trump administration will likely repeal Medical Device Tax: 5 takeaways
Naloxone price hikes could hurt efforts to reduce opioid-related deaths in US
JHL Biotech signs $236M biosimilar deal with Sanofi

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars